Alogabat – (2230009-48-8)

Alogabat (developmental code names RG-7816 and RO7017773) is an α5 subunit-containing GABAA receptor positive allosteric modulator under development for the treatment of pervasive developmental disorders (e.g., autism) and Angelman syndrome.

It is administered orally and is currently in phase 2 clinical trials as of June 2024. Alogabat is being developed by Roche.

The above information is displayed for information purpose only, and has not been reviewed by EON nor does EON attests or validates the accuracy nor does it constitutes a recommendation or validation.

Alogabat (developmental code names RG-7816 and RO7017773) is an α5 subunit-containing GABAA receptor positive allosteric modulator under development for the treatment of pervasive developmental disorders (e.g., autism) and Angelman syndrome.

It is administered orally and is currently in phase 2 clinical trials as of June 2024. Alogabat is being developed by Roche.

The above informationis displayed for information purpose only, and has not been reviewed by EON nor does EON attests or validates the accuracy nor does it constitutes a recommendation or validation.

Sources:

https://en.wikipedia.org/wiki/Alogabat
https://pubchem.ncbi.nlm.nih.gov/compound/134588268
https://www.medchemexpress.com/alogabat.html
https://www.medkoo.com/products/48378
https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=21578&isClinicalTrial=True

Other Names	Alogabat, Alogabat [INN], 0HPA4GK3UH, Alogabat [USAN]
IUPAC Name	6-[[5-methyl-3-(6-methylpyridin-3-yl)-1, 2-oxazol-4-yl]methoxy]-N-(oxan-4-yl)pyridazine-3-carboxamide
CAS	2230009-48-8
Molecular Weight	409.4
Molecular Formula	C21H23N5O4
SMILES	CC1=NC=C(C=C1)C2=NOC(=C2COC3=NN=C(C=C3)C(=O)NC4CCOCC4)C

Products

Consulting & Services

Check Out Our Research And Updates

Alogabat – (2230009-48-8)

Alogabat (developmental code names RG-7816 and RO7017773) is an α5 subunit-containing GABAA receptor positive allosteric modulator under development for the treatment of pervasive developmental disorders (e.g., autism) and Angelman syndrome.

It is administered orally and is currently in phase 2 clinical trials as of June 2024. Alogabat is being developed by Roche.

The above informationis displayed for information purpose only, and has not been reviewed by EON nor does EON attests or validates the accuracy nor does it constitutes a recommendation or validation.

Sources:

https://en.wikipedia.org/wiki/Alogabat
https://pubchem.ncbi.nlm.nih.gov/compound/134588268
https://www.medchemexpress.com/alogabat.html
https://www.medkoo.com/products/48378
https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=21578&isClinicalTrial=True

About Us

Products

Services

Quick Contact

Check Out Our Research And Updates

Alogabat – (2230009-48-8)

Alogabat (developmental code names RG-7816 and RO7017773) is an α5 subunit-containing GABAA receptor positive allosteric modulator under development for the treatment of pervasive developmental disorders (e.g., autism) and Angelman syndrome.

It is administered orally and is currently in phase 2 clinical trials as of June 2024. Alogabat is being developed by Roche.

The above informationis displayed for information purpose only, and has not been reviewed by EON nor does EON attests or validates the accuracy nor does it constitutes a recommendation or validation.

Sources:

https://en.wikipedia.org/wiki/Alogabat https://pubchem.ncbi.nlm.nih.gov/compound/134588268 https://www.medchemexpress.com/alogabat.html https://www.medkoo.com/products/48378 https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=21578&isClinicalTrial=True

Related products

Quick Contact

https://en.wikipedia.org/wiki/Alogabat
https://pubchem.ncbi.nlm.nih.gov/compound/134588268
https://www.medchemexpress.com/alogabat.html
https://www.medkoo.com/products/48378
https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=21578&isClinicalTrial=True